New targeted treatment approved for children with brain cancer
A new targeted treatment which could transform the lives of children with brain tumours has been approved for use on the NHS.
The combination of dabrafenib and trametinib can now be used for patients aged one and over with either low-grade or high-grade glioma with the genetic mutation BRAF V600E.
Gliomas are the most common type of brain cancer in children and young people.
They develop from the glial cells, which support the nerve cells of the brain and spinal cord.
